OFP011 cyclic peptide as a multifunctional agonist for opioid/neuropeptide ff receptors with improved blood–brain barrier penetration
M Zhang, B Xu, N Li, R Zhang, Q Zhang… - ACS Chemical …, 2022 - ACS Publications
Mounting evidence indicates that the neuropeptide FF (NPFF) system is involved in the side
effects of opioid usage, including antinociceptive tolerance, hyperalgesia, abuse …
effects of opioid usage, including antinociceptive tolerance, hyperalgesia, abuse …
Neuropeptide FF and its receptors: therapeutic applications and ligand development
T Nguyen, J Marusich, JX Li… - Journal of medicinal …, 2020 - ACS Publications
The endogenous neuropeptide FF (NPFF) and its two cognate G protein-coupled receptors,
Neuropeptide FF Receptors 1 and 2 (NPFFR1 and NPFFR2), represent a relatively new …
Neuropeptide FF Receptors 1 and 2 (NPFFR1 and NPFFR2), represent a relatively new …
Analgesic tolerance and cross-tolerance to the bifunctional opioid/neuropeptide FF receptors agonist EN-9 and μ-opioid receptor ligands at the supraspinal level in …
Z Han, G Jin, J Tang, H Wang, D Guo, J Zhang - Neuropeptides, 2023 - Elsevier
The chimeric peptide EN-9 was reported as a κ-opioid/neuropeptide FF receptors
bifunctional agonist that modulated chronic pain with no tolerance. Many lines of evidence …
bifunctional agonist that modulated chronic pain with no tolerance. Many lines of evidence …
VF-13, a chimeric peptide of VD-hemopressin (α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects
B Xu, J Xiao, K Xu, Q Zhang, D Chen, R Zhang… - …, 2020 - Elsevier
Pharmacological evidence indicated a functional interaction between neuropeptide FF
(NPFF) and cannabinoid systems, and the cannabinoids combined with the NPFF receptor …
(NPFF) and cannabinoid systems, and the cannabinoids combined with the NPFF receptor …
Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid …
R Zhang, B Xu, Q Zhang, D Chen, M Zhang… - European Journal of …, 2020 - Elsevier
Chronic opioids treatment is impeded by the development of analgesic tolerance and opioid-
induced hyperalgesia. Recent studies have shown that multi-functional opioid compounds …
induced hyperalgesia. Recent studies have shown that multi-functional opioid compounds …
The cyclic peptide OFP011 functioned as a multifunctional agonist at opioid/neuropeptide FF receptors with improved blood-brain barrier penetration
Q Fang, M Zhang, B Xu, N Li, R Zhang, Q Zhang… - Authorea …, 2024 - authorea.com
BACKGROUND AND PURPOSE A recently discovered multi-target opioid/neuropeptide FF
(NPFF) receptor agonist, DN-9, exhibited peripherally acting analgesia. To improve its …
(NPFF) receptor agonist, DN-9, exhibited peripherally acting analgesia. To improve its …
多靶点肽类镇痛药物的研究进展
方泉， 李宁， 许彪， 王锐 - 药学进展, 2019 - pps.cpu.edu.cn
Mu 阿片受体为吗啡和芬太尼等传统阿片类镇痛药物的主要作用靶点. 传统的阿片类镇痛药物
广泛用于中度和重度疼痛的临床治疗, 但长期使用该类药物会引起镇痛耐受和成瘾等副作用 …
广泛用于中度和重度疼痛的临床治疗, 但长期使用该类药物会引起镇痛耐受和成瘾等副作用 …
[PDF][PDF] Fmoc solid-phase synthesis of RF9 optimization with mass spectrometry verification
M Orocz, K Hartman, M Smoluch, J Silberring… - Current Issues in …, 2022 - sciendo.com
The RF9 compound, which is an antagonist of the FF neuropeptide receptors is used as a
therapeutic substance to improve the effectiveness of opioids in the chronic treatment of …
therapeutic substance to improve the effectiveness of opioids in the chronic treatment of …